Eli Lilly and Company (NYSE:LLY) Trading Down 1.2% - Here's Why

Key Points

• Despite a 1.2% intraday dip, Eli Lilly reported a blowout Q1 — EPS $8.55 vs. $6.97 and revenue of $19.8B — and raised FY2026 guidance to $35.50–37.00, signaling strong underlying fundamentals.
• Growth is being driven by GLP‑1 momentum — injectable Mounjaro (now the world’s top‑selling drug) and oral Foundayo — and Lilly pledged an additional $4.5B (>$21B total) to expand Indiana manufacturing to support rollout.
• Analysts have lifted price targets and the consensus is a Moderate Buy (~$1,217), but short‑term risks include reports of a ~$8B bond sale to fund acquisitions and rising competition from Novo Nordisk’s oral GLP‑1 launch.

Eli Lilly and Company (NYSE:LLY - Get Free Report) dropped 1.2% on Thursday . The company traded as low as $967.10 and last traded at $974.8210. Approximately 3,346,273 shares were traded during mid-day trading, an increase of 4% from the average daily volume of 3,208,447 shares. The stock had previously closed at $987.05.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q1 beat-and-raise: Lilly reported a blowout Q1 with outsized revenue and raised guidance, which drove the recent rally and underpins long-term growth expectations. LLY Stock Pops 16% After Beat-and-Raise Q1
• Positive Sentiment: Product momentum: Oral GLP‑1 Foundayo and injectable Mounjaro remain major revenue drivers (Mounjaro is now the world’s top-selling drug), supporting earnings visibility and premium valuation. Lilly's Oral GLP-1 Pill Foundayo Starts Strong
• Positive Sentiment: Capacity build: Lilly pledged another $4.5B to expand Indiana manufacturing (bringing total commitments >$21B), reducing future supply risk and supporting rollout scale-up for GLP‑1s and biologics. Lilly commits additional $4.5 billion across Indiana manufacturing sites
• Neutral Sentiment: Analyst stance and risk framing: Firms like Guggenheim reiterated buy ratings and some boutiques argue the market overreacted to an FDA adverse-event report—supporting the view that current pullbacks may be tactical rather than fundamental. Wolfe Research says market reaction appears overdone Guggenheim reiterates Buy
• Negative Sentiment: Financing chatter: Reports that Lilly plans to sell roughly $8B of bonds to fund acquisitions have spooked some traders—new debt (or M&A) can raise short-term uncertainty around capital allocation. Market Chatter: Eli Lilly Plans to Sell About $8 Billion of Bonds
• Negative Sentiment: Competitive pressure: Novo’s strong oral GLP‑1 launch and raised guidance highlight that the obesity/weight‑loss market is evolving quickly; increased competition could weigh on Lilly’s market share and pricing over time. Novo Nordisk Could Win the Oral GLP-1 Race

Wall Street Analysts Forecast Growth

Several analysts have commented on LLY shares. JPMorgan Chase & Co. lifted their target price on shares of Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the stock an "overweight" rating in a research note on Thursday, February 5th. TD Cowen upped their target price on Eli Lilly and Company from $960.00 to $1,250.00 and gave the company a "buy" rating in a research note on Thursday, January 29th. Wells Fargo & Company upped their price objective on shares of Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the company an "overweight" rating in a research note on Thursday, February 5th. Loop Capital set a $1,200.00 target price on shares of Eli Lilly and Company in a report on Tuesday, February 10th. Finally, Truist Financial reaffirmed a "buy" rating on shares of Eli Lilly and Company in a research note on Monday, February 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $1,217.59.

Eli Lilly and Company Stock Performance

The stock's 50 day moving average price is $945.26 and its 200 day moving average price is $989.70. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. The firm has a market cap of $918.03 billion, a PE ratio of 34.63, a P/E/G ratio of 1.08 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.97 by $1.58. The firm had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm's quarterly revenue was up 55.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities analysts forecast that Eli Lilly and Company will post 35.58 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be paid a $1.73 dividend. The ex-dividend date is Friday, May 15th. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. Eli Lilly and Company's dividend payout ratio is 24.58%.

Hedge Funds Weigh In On Eli Lilly and Company

A number of institutional investors have recently added to or reduced their stakes in the company. 10Elms LLP boosted its stake in shares of Eli Lilly and Company by 33.3% during the 3rd quarter. 10Elms LLP now owns 40 shares of the company's stock valued at $31,000 after buying an additional 10 shares during the last quarter. M.E. Allison & CO. Inc. grew its holdings in Eli Lilly and Company by 0.7% during the 4th quarter. M.E. Allison & CO. Inc. now owns 1,477 shares of the company's stock worth $1,587,000 after acquiring an additional 10 shares in the last quarter. Tanager Wealth Management LLP increased its position in shares of Eli Lilly and Company by 2.6% in the 4th quarter. Tanager Wealth Management LLP now owns 395 shares of the company's stock worth $424,000 after purchasing an additional 10 shares during the last quarter. Morey & Quinn Wealth Partners LLC raised its stake in shares of Eli Lilly and Company by 1.5% in the 4th quarter. Morey & Quinn Wealth Partners LLC now owns 661 shares of the company's stock valued at $710,000 after purchasing an additional 10 shares in the last quarter. Finally, Wealthspan Partners LLC lifted its position in shares of Eli Lilly and Company by 0.5% during the fourth quarter. Wealthspan Partners LLC now owns 2,110 shares of the company's stock worth $2,268,000 after purchasing an additional 10 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.